No Data
No Data
Buy Rating for Larimar Therapeutics Backed by Strong Clinical and Financial Outlook
Larimar Therapeutics Files for $300M Mixed Shelf Offering
Larimar Therapeutics | 10-Q: Quarterly report
Larimar Therapeutics' Cash, Cash Equivalents, And Marketable Securities Of $239M As Of March 31, 2024, Extends Projected Cash Runway Into 2026
Larimar Therapeutics' Cash, Cash Equivalents, And Marketable Securities Of $239M As Of March 31, 2024, Extends Projected Cash Runway Into 2026
Larimar Therapeutics Q1 2024 GAAP EPS $(0.27) Beats $(0.28) Estimate
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.28) by 3.57 percent. This is a 80 percent decrease over losses of $(0
Larimar Therapeutics 1Q Loss $14.7M >LRMR
Larimar Therapeutics 1Q Loss $14.7M >LRMR
No Data